Breast Cancer Clinical Trial
Official title:
Irinotecan for Advanced and Metastatic Breast Cancer Previously Treated Using Anthracyclines- and Taxanes-containing Regimens: Protocol for a Phase II, Open-label, Single-arm Trial
Verified date | June 2018 |
Source | Liaoning Tumor Hospital & Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial aims to evaluate the safety and efficacy of third-line or later irinotecan treatment for locally recurrent or metastatic breast cancer among Chinese patients who have received at least two regimens containing anthracyclines and taxanes.
Status | Active, not recruiting |
Enrollment | 124 |
Est. completion date | December 2021 |
Est. primary completion date | January 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Age of 18-70 years; - Female patients with histologically or cytologically confirmed breast cancer; - Patients with locally recurrent or metastatic breast cancer who have been treated with at least two chemotherapy regimens; - Measurable lesions (based on computed tomography or magnetic resonance imaging) that have a longest diameter of = 10 mm based on the RECIST v1.1 criteria and a shortest lymph node diameter of = 15 mm; - Eastern Cooperative Oncology Group (ECOG) grade 0-2; - Life expectancy of = 12 weeks; - Adequate bone marrow capacity, hepatic functional reserve, and renal functional reserve within 7 days before screening: Absolute neutrophils count: 1.5 × 109/L Hemoglobin: = 9.0 g/dL; - Platelet count: = 80 × 109/L Total bilirubin: < 1.5 times the ULN Aspartate and alanine transaminases: = 2.5 times the ULN (= 5 times the ULN for liver metastases) Alkaline phosphatase:< 4 times the ULN Serum creatinine: = 1.5 times the ULN - Women of childbearing age requiring effective contraception; - Provision of informed consent. Exclusion Criteria: - Receiving chemotherapy, radiotherapy, HER2/neu-targeted drugs (including trastuzumab), or hormonal therapy within 3 weeks; - Breast cancer patients who do not receive local treatment and develop brain and dural metastasis. However, patients will be eligible if corticosteroids for brain and dural metastasis have been withdrawn for at least 4 weeks, if the signs and/or symptoms of brain metastasis have been stable for = 4 weeks, and if imaging findings confirm that the disease is stable between the screening and 4 weeks earlier; - Severe cardiovascular injury (congestive heart failure of class II or worse based on the New York Heart Association classification), unstable angina, myocardial infarction, or severe arrhythmia during the past 6 months; - A history of human immunodeficiency virus infection, chronic hepatitis B, or hepatitis C (high viral DNA copyl DNA ti) at the active phase; - Clinical evidence of other severe active infection; - Patients with homozygous mutations in UGT1A1*6 and/or UGT1A1*28 (these patients are susceptible to irinotecan-induced diarrhea); - Patients with allogeneic organ transplants that require immunosuppressive therapy; - A history of other malignancies within 5 years, except for cured cervical carcinoma in situ or basal cell skin cancer. Women who are pregnant, lactating, or within their childbearing age but not using adequate contraception; - Drug abuse and medical, psychological, or social conditions that could interfere with the patient's ability to consent or that might affect the study's results; - Known or suspected being allergy to the studied drug or any other drug administered in the study; - Any unstable condition that might jeopardize the patient's safety and compliance. |
Country | Name | City | State |
---|---|---|---|
China | Cancer Hospital of China Medical University | Shenyang | Liaoning |
Lead Sponsor | Collaborator |
---|---|
Liaoning Tumor Hospital & Institute |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate (ORR) | The ORR will be calculated based on the number of patients who achieve a complete or partial response divided by the total sample size. | 1 year | |
Secondary | Progression-free survival(PFS) | The PFS interval will be calculated from the start of irinotecan treatment to the first instance of tumor progression, treatment failure, or death from any cause. Overall survival will be calculated from the start of irinotecan treatment to death from any cause. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |